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Asthma and chronic obstructive pulmonary disease (COPD) are chronic 
inflammatory disorders of the airway. Eosinophils are the major inflammatory 
cells involved in pathogenesis of asthma, whereas neutrophils are prominent in 
the airway of COPD patients. The trafficking of eosinophils and neutrophils 
into the site of inflammation is directed by cytokines and chemokines. 
Chemokines are members of cytokines, which weigh between 8 - 1 0 kDa, 
responsible for signaling chemotaxis of leukocytes. Increased oxidative stress 
is observed in smokers and patients with COPD, suggesting its role in 
pathogenesis of COPD. 8-isoprostane, which is formed by lipid peroxidation 
of arachidonic acid, is one of the most reliable biomarkers of oxidative stress. 
Collection and analysis of ingredients of exhaled breath condensate (EBC) is 
an evolving method in assessing inflammation in the lungs as this is a non-
invasive, easy to perform method and its collection can be repeated frequently. 
In this project, we investigate whether it is feasible to measure chemokines 
(like monocyte chemoattractant protein-1, growth related oncogene-a, 
monocyte-derived chemokine and eotaxin) and 8-isoprostane in EBC. The 
relationship between their levels in EBC and the severity of asthma and COPD 
will also be assessed. 
Patients with asthma and COPD were recruited from the respiratory clinic of 
the Prince of Wales Hospital. Age and sex matched controls were recruited 
from healthy volunteers. EBC was collected with the subjects breathing tidally 
for 10 minutes through a special device (EcoScreen, Jaeger, Germany) and 
stored in -70°C until analysis. Chemokines and 8-isoprostane concentrations in 
EBC were determined by sandwich ELISA. 
Thirty-two patients with COPD, of which 21 were on inhaled corticosteroid 




isoprostane than controls (14.2pg/ml vs 6.0pg/ml, p<0.001). The severe COPD 
patients with low lung function (forced expiratory volume at 1 second [FEVl] 
<50% predicted) had a higher level of EBC 8-isoprostane when compared to 
the less severe COPD patients (FEVl >50% predicted) (p=0.045). The level of 
GRO-a in EBC was lower in the COPD patients than the controls (45.4pg/ml 
vs 46.0pg/ml, p=0.02). 
Fifty-four patients with asthma, of which 29 were on inhaled corticosteroid 
treatment, were recruited. Patients with asthma on inhaled corticosteroid 
treatment had an elevated exhaled eotaxin (18.5pg/ml) and MDC (120.4pg/ml) 
as compared with their steroid-naive counterparts (Eotaxin: 17.9pg/ml, 
p=0.02; MDC: 117.4pg/ml, p=0.01) and controls (Eotaxin: 17.4pg/ml, 
p=0.001; MDC: 117.2pg/ml, p=0.02). Exhaled MDC correlated with 
peripheral blood IgE level (r=0.41, p=0.04) in steroid free asthmatic patients. 
It was feasible to measure exhaled biomarkers in patients with obstructive 
lung diseases. The level of exhaled 8-isoprostane, GRO-a and MCP-1 were 
altered in patients with COPD, which was associated with the severity of the 
disease and airway inflammation in these patients. Higher level of exhaled 
eotaxin and MDC in patients with asthma who were on inhaled corticosteroid 
treatment suggested that subjects on inhaled corticosteroid treatment (ICS) had 
more severe inflammation in the airway. Further studies are needed to 
investigate the role of chemokines in COPD and asthma, and the usefulness of 


































有較少 GRO- a (45.4pg/ml vs 46.0pg/ml, p=0.02)� 
本硏究招募了 44名哮喘病患者’其中29名患者接受吸入式類固醇 
治療(類固醇組）。類固醇組的呼氣冷凝液中的Eotaxin(l8.5pg/ml)和 
MDC(120.4pg/ml)分別比非類固醇組（Eotaxin: 17.9pg/ml, p=0.02; MDC: 












ACQ Asthma control questionnaire 
BAL Bronchoalveolar lavage 
CC CC chemokine 
CCL CC ligand. Also known as CC chemokine 
CCR CC chemokine receptor 
CEA Serum carcinoembryonic antigen 
CX3C CX3C chemokine 
CXC CXC chemokine 
CXCL CXC ligand. Also known as CXC chemokine 
CXCR CXC chemokine receptor 
ECM Extracellular matrix 
ECP Eosinophilic cytotoxic protein 
FEVl Forced expiratory volume at 1 second 
FVC Forced vital capacity 
GRO- a Growth regulated oncogene a 
HAT Histone acetyltransferase 
HDAC Histone deacetylase 
LT Cysteinyl leukotriene 
LTB4 Cysteinyl leukotriene B4 
LTC4 Cysteinyl leukotriene C4 
LTD4 Cysteinyl leukotriene D4 
LTE4 Cysteinyl leukotriene E4 
MBP Major basic protein 
MCP-1 Monocyte chemoattractant protein 1 
MDC Macrophage derived chemokine 




RANTES Regulated on activation, normal T cell expressed and secreted. 
Also known as CCL5. 





The main function of the lungs is to carry out gas exchange, during which the 
lung is exposed to gases, particulates and infectious agents. The lungs possess 
a well-developed immune system to prevent invading pathogens. Yet, in 
subjects with asthma, the immune system responds excessively to innoxious 
agents such as pollen grains and dog hair. The mechanisms underlying this 
"exaggerated" response or so call "bronchial hyperresponsiveness" are not 
entirely clear. On the other hand, in subjects with chronic obstructive 
pulmonary disease (COPD), repeated exposure of chemical assault such as 
cigarette smoke damages the small airways and parenchyma of the lungs. This 
leads to impairment of ventilation and the development of symptoms such as 
shortness of breath on exertion in subjects with COPD. 
1.1 Prevalence of COPD and asthma in Hong Kong 
The prevalence of COPD is generally high in countries where the consumption 
of cigarette smoke per capita is substantial. The prevalence of COPD in China 
in a study conducted in 1990 was 26.2/1000 among men and 23.7/1000 among 
women [National Heart, Lung and Blood Institute, World Health 
Organization, 2004]. The Population Health Survey in 2003/2004 estimated 
that 2.5% Hong Kong people aged 45 and above were diagnosed to have 
COPD [Non-Communicable Disease Aware, Centre for Health Protection of 
the Department of Health, 2004]. 
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It has been estimated that around 300 million people in the world currently 
suffer from asthma, and there will be a striking increase in the number of 
asthmatics in the next two decades as the world's population in urban area is 
projected to have an increase from 45% to 59% in 2025. The prevalence of 
clinical asthma in Hong Kong was estimated to be 6.2% in 2004 [Masoli et al.， 
2004]. 
1.2 Players in pathogenesis of COPD 
COPD, which encompasses chronic bronchitis and emphysema, is a disorder 
characterized by airflow limitation which is not fully reversible [Siafakas et al. 
1995]. The predominant symptom of patients with COPD is breathlessness, 
which is caused by progressive obstruction of the airflow of the lungs. 
Pathological lesions contributing to the airflow limitation in patients with 
COPD include inflammation of the large (bronchitis) and small airways 
(bronchiolitis), as well as the destruction of alveolar walls and alveolar 
airspace enlargement (emphysema) [MacNee and Rahman, 2001]. 
Neutrophils and oxygen free radical mediated airway inflammation probably 
play an important part in the pathogenesis of COPD. 
It is observed that there is influx of neutrophils into the lungs and airway 
lumen of patients with COPD [Thompson et al., 1989; Linden et al., 1993; 
Lacoste et al., 1993; Keatings et al., 1996]. Neutrophil derived 
myeloperoxidase, a degranulation product of neutrophils, was augmented in 
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the bronchoalveolar lavage (BAL) fluid in patients with COPD, and this 
reflected the activation of neutrophils and excessive neutrophil degranulation 
in the the airway of patients with COPD [Hathaway et al., 1993; Lacoste et al.’ 
1993]. The severity of emphysema was positively associated with the 
distribution of interstitial neutrophil elastase in lung tissue [Damiano et al., 
1986]. All the data suggest that neutrophils play an important role in 
pathogenesis of COPD by secreting excessive proteases, which contribute to 
the ongoing airway inflammation and lung parenchymal destruction. 
Concerning oxygen free radical mediated airway inflammation, cigarette 
smoke, a known risk factor related to COPD, induces inflammatory leukocytes 
to produce oxidants such as oxygen free radicals [MacNee and Rahman, 
2001]. Surging in the production of superoxide anion from peripheral blood 
neutrophils was observed in patients during acute exacerbations of COPD 
when compared to stable patients [Morrison et al., 1999]. Circulating F2-
isoprostante，a by-product of lipid peroxidation by free radicals, was observed 
to be increased in smokers [Morrow et al., 1995]. Local production of 
superoxide anion in the lungs was evidenced by an augmentation of this 
oxidant in the cell-free BAL fluid from patients with COPD [Pinamonti et al., 
1996]. The level of exhaled ethane, resulting from lipid peroxidation, was not 
only increased in patients with COPD when compared with controls, but also 
correlated negatively with lung function [Paredi et al., 2000]. The evidence 
thus all supported oxygen free radical mediated airway inflammation in 
COPD. 
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1.3 Players in pathogenesis of asthma 
Asthma, a disease which is characterized by reversible airflow obstruction 
with symptoms of intermittent wheeze and shortness of breath, is 
characterized by airway hyperresponsiveness to common allergens and 
ongoing airway inflammation [Masoli, 2004]. The airway inflammation, at 
least in part, is thought to be related to the accumulation of eosinophils and T 
helper 2 cells (Th2) in airway mucosa. 
Early studies suggested a strong association between tissue eosinophils and 
asthma. Post mortem studies revealed that the predominant cell type 
infiltrating the asthmatic airways was eosinophils [Dunnill I960]. This 
observation was consistent with the bronchial biopsies and BAL studies 
[Djukanovic and Wilson et al., 1990; Bousquet et al.，1990]. Activated 
eosinophils participated in tissue inflammation and remodeling of asthma by 
secreting Th2 cytokines, growth factors and metalloproteases [Dubucquoi et 
al., 1994; Levi-Schaffer et al., 1995; Walz et al., 1993; Ohno et al., 1992; 
Shlopov and Hasty 1998; Schwingshackl et al., 1999; Levi-Schaffer F et al., 
1999], Following activation, eosinophils released oxygen free radicals that 
were involved in inflammation [Hamann 1996], and leukotrienes that could 
contract bronchial smooth muscle [Rabe et al., 1994]. In addition, activated 
eosinophils released basic proteins such as major basic protein (MBP) [Lewis 
et al., 1978] and eosinophil cationic protein (ECP) [Ackerman et al., 1985]. 
MBP was cytotoxic to human bronchial tissue explants and tracheal 
epithelium [Frigas et al.，1981; Frigas et al., 1980]. In addition, MBP could 
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impair the mucus clearance in the airway [Jacoby et al., 1988]. ECP is a more 
potent cytotoxic agent than MBP [Ackerman et al., 1985]. A surge in ECP was 
observed in the epithelium and submucosa of asthmatics when compared with 
controls [Djukanovic and Roche et al., 1990; Djukanovic and Wilson et al., 
1990]. The association between eosinophils or their products and the severity 
of asthma was supported by various BAL and induced sputum studies 
[Bradley et al., 1991; Bousquet et al., 1990; Louis et al., 2000; Louis et al., 
1997]. Moreover, bronchoscopic studies revealed that eosinophil counts 
declined after inhaled and oral corticosteroids therapy [Djukanovic et al., 
1992; Djukanovic et al., 1997; Wallin et al., 1999]. All these suggest that 
eosinophils do play an important part in the pathogenesis of asthma. 
Soon after bronchial allergen provocation, a reduction in Th2 cells in 
peripheral blood was observed in atopic asthmatics, suggesting the active 
recruitment of Th2 cells into the airways [Zlotnik and Yoshie, 2000]. Th2 cells 
perpetuate airway inflammation by secreting numerous cytokines, for instance, 
IL-4 that instructs isotype switching of B cells to produce IgE [Street and 
Mosmann, 1991], In addition, Th2 cells promote the expression of adhesion 
molecules to facilitate the adhesion of eosinophils to bronchial endothelium 
[Schleimer et al., 1992]. Furthermore, Th2 cells stimulate the production of 
IL-5, which in turn instructs the differentiation and promotes the survival, 
priming and activation of eosinophils [Sanderson, 1992]. Th2 cells also secrete 
the granulocyte macrophage colony stimulating factor (GM-CSF) that 
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prolongs the survival of eosinophils in asthma [Park et al.，1998]. All these 
studies support the pivotal role of Th2 cells in pathogenesis of asthma. 
1.4 The use of exhaled breath condensate in previous studies 
Conventional methods, such as the analysis of induced sputum and BAL fluid 
obtained from bronchoscopy, are used to monitor inflammation of the lower 
respiratory tract. However, these methods are limited by their repeatability 
because they are irritating and the procedure itself may provoke inflammatory 
responses. Scientists have been trying to search a new way to overcome the 
above disadvantages. Expired air not only consists of volatile gases such as 
carbon dioxide and nitric oxide, but also a water vapour saturated phase that is 
made up by aerosols from the airway lining fluid. This saturated water vapour 
can be collected on a cold surface by condensation. This collected fluid is 
called exhaled breath condensate (EBC). 
Collection and analysis of constituents of EBC has yielded promising results 
in various respiratory disorders. Hydrogen peroxide is a metabolite of 
oxidative metabolism and its level can reflect the oxidant activity in the tissue. 
An elevated level of hydrogen peroxide in the EBC was found in smokers, 
acute respiratory distress syndrome, and COPD, compared to normal subjects 
[Nowak et al., 1996; Sznajder et al.，1989; Wilson et al., 1992; Dekhuijzen et 
al., 1996]. A negative correlation was demonstrated between the level of 
hydrogen peroxide in EBC and the FEVl value in adult patients with asthma 
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[Antczak et al., 1997]. Leukotrienes (Lis) are lipid mediators derived from 
arachidonic acid via the 5-lipoxygenase pathways. Previous studies found that 
it was feasible to detect leukotrienes (LTs) in the EBC from both asthmatics 
and normal subjects [Becher et al., 1997; Hanazawa et al., 2000], Patients with 
moderate to severe persistent asthma demonstrated an increased level of 
LTE4, LTC4 and LTD4 in their EBC when compared to the mild asthmatic 
subjects and controls [Hanazawa et al, 2000]. Similarly, an augmented level 
of LTB4 in the EBC was observed in subjects with COPD when compared to 
controls [Kharitonov et al, 2001]. Nitrite is formed via oxidation of nitric 
oxide. Significant increase in nitrite in the EBC was found not only in patients 
with asthma, but also in clinically stable patient with cystic fibrosis when 
compared with controls [Hunt et al., 1995; Ho et al., 1998]. Reaction between 
nitric oxide and superoxide yields peroxynitrite, with the latter being further 
decomposed into nitrotyrosine. Previous study revealed an elevated level of 
nitrotyrosine in EBC was associated with a decrease in FEVl in patients with 
COPD [Ichinose et al., 2000]. 
8-isoprostane, which is formed via free radical catalysed peroxidation of 
arachidonic acid, reflects oxidative stress in the lungs. Airway inflammation in 
COPD results from an uncontrolled oxidative stress [Repine et al., 1997]. An 
increase in 8-isoprostane was observed in urine sample of patients with stable 
COPD [Pratico et al., 1998]. Several studies have shown that it is feasible to 
measure 8-isoprostane in EBC from patients with COPD. Augmented 8-
isoprostane in EBC was found in smokers with COPD, as compared with 
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healthy smokers and non smokers [Montuschi and Collins et al., 2000]. During 
exacerbation of COPD, 8-isoprostane in EBC was increased but declined 2 
weeks and 2 months after the exacerbation [Biernacki et al., 2003], However, 
it is not clear whether the level of 8-isoprostane, measured by the non invasive 
method of EBC collection, remains elevated in COPD patients who have 
quitted smoking, and the relationship between 8-isoprostane and lung function 
in these patients remains undefined. 
Cytokines such as interleukin 4 and interferon y can also be measured in EBC. 
Increased level of interleukin 4 but decreased level of interferon y was 
observed in EBC samples of children with asthma [Shahid et al., 2002]. The 
above mentioned molecules that could be identified in the EBC (hydrogen 
peroxide, LTs, nitrite, nitrotyrosine, cytokines such as interleukin 4 and 
interferon y) are relatively large molecules (of molecular weight up to 65kDa) 
[Shahid et al., 2002]. It is tempting to investigate whether chemokines, which 
are much smaller molecules (with a molecular weight of 8 to 10 kDa in 
general) and playing a key role in the trafficking of leukocytes (cells involved 
in the airway inflammation of asthma and COPD patients), are present in 
EBC. A brief introduction of chemokines is discussed in the following section. 
1.5 Brief overview of chemokines 
Chemokines are small peptides weighted between 8 - 1 0 kDa, with four 
conserved cysteines in primary amino acid sequence [Zlotnik and Yoshie, 
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2000]. They are divided into four subfamilies, on the basis of arrangement of 
two N-terminal cysteine residues: (1) CXC chemokines, of which the first two 
cysteine residues are separated by a single amino acid; (2) CC chemokines, in 
which the first two cysteine residues are adjacent to each other; (3) C 
chemokines that lack cysteines 1 and 3 of the typical chemokine structure; and 
(4) CX3C chemokines, which consist of 3 amino acids between the first two 
cysteines and belong to the membrane bound chemokine through a mucin-like 
structure. Chemokines induce migration and activation of leukocytes by 
forming gradients generated by the chemokine secreting cells. Chemokines are 
known to be secreted by a variety of immune cells and tissue such as 
epithelium and smooth muscle [Gutierrez-Ramos et al.，2000]. Under the 
influence of the gradient of chemokines, responding cells that express the 
relevant chemokine receptors migrate to their destination [Rossi and Zlotnik, 
2000]. The genes encoding CXC, C CX3C and CC chemokine are located in 
chromosomes 4，17，1 and 17 respectively [Zlotnik, 2003]. Chemokines that 
belong to the same subfamily share the same receptor that binds exclusively to 
the corresponding chemokine ligands. For example, CXCL9, 10 and 11 bind 
exclusively to CXCR3，whereas CXCL12 binds CXCR4 [Zlotnik, 2003]. On 
the other hand, some chemokines demonstrate functional redundancy, i.e., 
chemokines of different subfamily can exert overlapping function. The main 
function of CC chemokines is to attract monocytes-macrophages during 
inflammation, such as CCL17 which is produced by dendritic cells, whereas 
CXC chemokines attract neutrophils, such as CXCL15 which is produced by 
lung epithelial cells. Chemokine receptors are G protein coupled seven 
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transmembrane receptor. Different chemokine receptors are expressed 
simultaneously in the same cell type and sometimes the same cell. For 
example, CXCRl shares ligand IL-8/CXCL8 with CXCR2 and both receptors 
are co-expressed in neutrophils, monoyctes and natural killer cells [Morohashi 
et al., 1995]. The presence of the same receptor in different cells and the 
different receptors in the same type of cells may explain in part the 
overlapping function of some chemokines. 
Eotaxin and macrophage derived chemokine (MDC) are CC chemokines and 
their respective receptors are CCR3 and CCR4. Their production is regulated 
by IL-4 and IL-13 [Andrew et al.,1998; Li et al., 1999; Teran et al., 1999; 
Galli et al., 2000; Goebeler et al., 1997; Mochizuki et al., 1998]. CCR3 is 
highly expressed in eosinophils [Zlotnik et al., 1999; Rossi et al., 2000]. 
Studies have found that eotaxin is the most potent chemoattractant for 
eosinophils [Collins et al., 1995; Jose and Adcock et al., 1994; Jose and 
Griffiths-Johnson et al., 1994; Gerber et al., 1997; Heath et al., 1997; Ying et 
al., 1997; Sabroe et al., 1999; Ying et al., 1999; Tachimoto et al., 2000], In 
addition, previous studies have shown that airway epithelial cells are one of 
the sources of eotaxin secretion that are able to recruit and activate eosinophils 
within the airspaces [Matsukura et al., 2001; Matsukura et al, 1999; Cook et 
al., 1998]. Taken together, these studies highlight the association between 
eotaxin and eosinophils. MDC was constitutively expressed in monocytes-
derived dendritic cells [Godiska et al., 1997] and thymic epithelial cells 
[Chantry et al.’ 1999]. MDC recruits Th2 cells into sites of allergic 
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inflammation [Imai et al., 1999]. Patients with atopic dermatitis have 
demonstrated elevated MDC in serum [Kakinuma et al., 2002]. Serum MDC 
correlates with peripheral blood eosinophils and serum IgE of asthmatics 
[Sekiya et al., 2002]. Collectively, these studies suggest the role of MDC in 
allergic diseases. 
Eotaxin and MDC play an important role in allergic disease like asthma. So 
far, there is only one study that attempted to measure eotaxin and MDC in the 
EBC of paediatric subjects with asthma and the investigators noted that MDC 
in EBC was increased as the severity of asthma increased [Leung et al., 2004]. 
It is unknown whethter eotaxin and MDC can be measured in the adult 
asthmatic airway and whether there are any differences in their levels between 
subjects with different severity of asthma and controls. The information may 
be very useful for developing non-invasive monitoring of airway inflammation 
in subjects with asthma. 
Monocyte chemoattractant protein 1 (MCP-1) is another CC chemokine, of 
which the receptor is CCR2. Elevated expression of MCP-1 and CCR2 was 
found in macrophages and epithelial cells in patients with COPD from 
bronchial biopsy specimens [de Boer et al., 2000]. The increase in neutrophils 
and macrophages in BAL was accompanied by a surge in MCP-1 in lung 
tissue after ozone exposure in the mouse model [Zhao et al., 1998]. Growth 
regulated oncogene a (GRO-a) is CXC chemokine and its receptor is CXCR2. 
The level of GRO-a was increased in induced sputum in patients with COPD 
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when compared to controls [Pesci et al.，1998]. MCP-1 and GRO- a seemed 
to play a role in the airway inflammation of subjects with COPD. Their levels 
have been shown to increase in the induced sputum of patients with COPD 
[Traves et al., 2002]. However, it is unsure whether MCP-1 and GRO- a can 
be measured in the EBC of COPD patients. Collection of EBC will have 
advantages over induced sputum due to its non-irritating nature. 
With the limited data available from the literature, it is unsure whether 
chemokines are measurable in the EBC in adult patients with asthma or 
COPD. If chemokines are measurable in these subjects, it would be interesting 
to assess any relationship between their levels and the severity of the airway 
disease. The measurement of markers, such as chemokines, in the EBC of 
adult subjects with asthma and COPD opens a non-invasive way to assess the 
airway inflammation without the need to go through conventional invasive 
methods like bronchial biopsies and BAL. 
1.6 Objective of this study 
The aims of this study are to investigate: 
1. whether it is feasible to measure MCP-1 and GRO-a (chemokines 
related to monocytic and neutrophilic mediated inflammation), and 8-
isoprostane (an oxidative stress marker) in the EBC of COPD subjects 
and controls; 
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2. whether it is feasible to measure MDC and eotaxin (the chemokine 
related to Th2 helper cells and eosinophilic inflammation) in the EBC 
of adult subjects with asthma and controls; and 
3. any relationship between the EBC levels of chemokines and 8-
isoprostane in relation to the severity of asthma and COPD. 
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Materials and methods 
2.1 Study population 
2.1.1 Patients with COPD and control subjects 
Thirty-two COPD patients were recruited from the respiratory clinic and the 
general medical clinic of the Prince of Wales Hospital, a University teaching 
hospital in Hong Kong. All the subjects had a diagnosis of COPD according to 
the Global Initiative of Obstructive Lung Disease Guideline [National Heart, 
Lung and Blood Institute, World Health Organization, 2004] and were on 
bronchodilator treatment. In addition, all their previous lung function studies 
did not show any significant reversibility to bronchodilator (FEVi increased 
by less than 200ml and 15% of baseline value after 400mcg of salbutamol). 
Their CXRs also showed no radiographic evidence of fibrosis or 
bronchiectatic changes. All these patients were ex-smokers (for at least 3 
months) with at least 10 pack years of smoking history. All patients were not 
on aspirin, non-steroidal anti-inflammatory agents or systemic steroids. They 
had neither intercurrent infection nor exacerbation, and there was no change of 
medications for the airway disease for at least 8 weeks prior to the study. Age 
and sex matched non-smoking subjects with no known chronic respiratory 
diseases and recent respiratory symptoms for at least 8 weeks were recruited 
as controls. These control subjects were participants of another project in the 
Chinese University of Hong Kong. They were healthy non-smoking persons 
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from the community who were selected by random telephone digit dialing and 
invited to have lung function assessment. 
2.1.2 Patients with asthma and control subjects 
Adult subjects with age >18 years were recruited from the asthma clinic of the 
same hospital. Asthma was diagnosed according to the British Thoracic 
Society criteria [British Thoracic Society, 2003]. Controller and rescue 
therapies for asthma were unchanged during the past 6 weeks prior to the 
assessment and in addition, the subjects had no exacerbation of asthma over 
the past 6 weeks. Current cigarette smokers or subjects on systemic 
corticosteroids were excluded from this study. Sex and age matched 
volunteers free of respiratory diseases were recruited as control subjects. 
Control subjects were all non-smokers, with no known respiratory diseases 
like asthma, chronic obstructive pulmonary disease or bronchiectasis. They 
had no chronic respiratory symptoms and were free from any respiratory tract 
infection for 6 weeks prior to the assessment. 
The study protocol was approved by the Research Ethics Committee of the 
Chinese University of Hong Kong and each subject had given informed 
written consent. 
2.2 Lung fimction 
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Spirometry (Vitalograph, Model S, UK) was performed according to the 
American Thoracic Society standards [American Thoracic Society, 1987], The 
reference FEVi and FVC values based on the population standard by Lam et al 
were adopted for this study [Lam et al., 1983]. Forced expiratory volume in 1 
second (FEVi) and forced vital capacity (FVC) were measured pre and post 
bronchodilator therapy (salbutamol 400mcg). 
2.3 Dyspnoea score measurement of patients with COPD 
Six-minute walk test was performed after spirometry according the ATS 
guidelines [American Thoracic Society, 2002], The subjective degree of 
dyspnoea after the 6 minute walk test was assessed by Borg score (score from 
Oto 10) [Borg, 1982], 
2.4 Classification of patients and asthma severity 
Asthma patients were classified into patients who were on inhaled 
corticosteroid (ICS) and those not on ICS in the past 8 weeks. The respiratory 
symptoms and degree of asthma control were measured in a standardized way 
by the Asthma Control Questionnaire (ACQ) by Juniper et al. [Juniper, et al., 
1999]. The ACQ score ranges from 0 to 6 with a higher score suggesting 
poorer asthma control. 




Skin prick test was performed with a panel of eight common aeroallergens to 
the forearm using standard methods [Pepys, 1975]. A wheal size of larger than 
3 mm 15 minutes after skin prick was considered as a positive test. Allergens 
including Dermatophagoides pteronyssinus, Dermatophagoides farinae, house 
dust, cockroach, Cladosporidium, Bermuda grass, cat fur and dog hair (ALK-
Allello, Denmark) were used. Blood was taken for total serum IgE level and 
eosinophil count. 
2.6 Collection of exhaled breath condensate 
EBC was collected using the EcoScreen (Jaeger, Germany) according to 
manufacturer instructions. The collection was done from 9 to 10 am in the 
morning. After rinsing their mouth, the recruited subjects breathed tidally 
through a mouthpiece that was connected through a unique one-way valve into 
a cooled collection tube where vapours, aerosols and moisture in the breath 
condensed along the walls of the tube. The design of the system prevents 
salivary contamination of EBC. Each subject was asked to breathe through the 
collection kit for 10 minutes while wearing a noseclip with more than 1 ml of 
EBC collected. EBC was stored immediately at -lOX until analysis. 
2.7 Measurement of constituent in EBC 
2.7.1 Measurement of 8-isoprostane, MCP-1 and GROa in patients with 
COPD and the corresponding control subjects 
I 
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The concentrations of 8-isoprostane, MCP-1 and GROa in the frozen EBC 
were measured in one batch. Concentrations of these markers were measured 
by sandwich enzyme immunoassays (8-isoprostane from Cayman Chemical, 
Ann Arbor, MI, USA; MCP-1 and GROa from R & D Systems, Minneapolis, 
MN, USA) according to instructions provided by the manufacturers. The 
specificity of 8-isoprostane assay was 100%. The intra-assay and inter-assay 
variabilities of 8-isoprostane, MCP-1 and GROa were <10%, as stated by the 
manufacturers. The sensitivities of this method for 8-isoprostane, MCP-1 and 
GROa were 4, 5 and 10 pg/ml, respectively. 
2.7.2 Measurement of eotaxin and MDC of patients with asthma and the 
corresponding control subjects 
The concentrations of eotaxin and MDC in the frozen EBC were measured in 
one batch. Concentrations of these markers were measured by sandwich 
enzyme immunoassays (eotaxin from Biosource International, Camarillo, CA. 
USA; MDC from R & D Systems, Minneapolis, MN, USA) according to the 
manufacturers' instructions. The intra-assay and inter-assay variabilities of 
eotaxin and MDC were <10%, as stated by the manufacturers. The 
sensitivities of this method for eotaxin and MDC and were 2.2 and 62.5pg/ml 
respectively. 
2.8 Reproducibility of exhaled breath constituent 
18 
2.8.1 Assessment of reproducibility of the exhaled MCP-1, GROa and 8-
isoprostane measurements 
Intra-subject reproducibility of 8-isoprostane, MCP-1 and GROa was assessed 
by collection of EBC in 10 healthy volunteers working in the investigator's 
laboratories. A total of 10 subjects had EBC collected as described above at 
the same time (09:00 to 10:00) for 2 consecutive days. All subjects had no 
known respiratory disease and were free from symptoms of respiratory tract 
infection or medication use for at least 4 weeks prior to study. 
2.8.2 Assessment of reproducibility of the exhaled eotaxin and MDC 
measurement 
Intra-subject reproducibility of eotaxin and MDC was assessed by collection 
of EBC in 6 healthy volunteers working in the investigator's laboratories as 
described previously [Leung et al., 2004]. EBC was collected as described 
above at the same time (09:00 to 10:00) for 6 consecutive days. All subjects 
had no known respiratory disease and were free from symptoms of respiratory 
tract infection or medication use for at least 4 weeks prior to study. 
2.9 Statistical analysis 
Data were analyzed by the Statistical Package of the Social Science (SPSS) 
Statistical software for Window version 11.5 (SPSS Inc，Chicago, DL, USA). 
Demographic data of the subjects were presented as means 土 standard 
, deviation (SD). The 8-isoprostane, GROa, MCP-1, MDC and eotaxin levels 
» 
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were expressed as median and interquartile range (IQR). When their levels 
were below the detection limit of the sandwich enzyme immunoassay kits, half 
of the values of the lower detection limit were taken for statistical analysis. A 
p-value <0.05 was considered as statistically significant. The 8-isoprostane, 
GROa and MCP-1 levels were compared between the COPD patients and 
control groups, whereas the eotaxin and MDC levels were compared between 
the asthma subjects and control groups, by Kruskal-Wallis test or Mann-
Whitney rank sum test as appropriate. Correlation of lung function, symptoms, 
and peripheral white cell count with the levels of exhaled breath markers were 
assessed by Spearman's rank correlation test. Bland and Altman's method was 
used to assess repeatability of 8-isoprostane, GROa and MCP-1 in the EBC 
[Bland and Altman, 1986]. Co-efficient of variation was used to assess the 





3.1 Patients with COPD and corresponding control subjects 
Demographic data of the patients are shown in Table 1. Patients with COPD 
were divided into two groups. Group 1 had mild-to-moderate COPD with 
FEVI > 50% predicted. Group 2 COPD had severe COPD with FEVi < 50% 
predicted normal. Among the COPD patients, 21 (66%) and 11 (34%) were on 
inhaled corticosteroid (ICS) and oral theophylline treatment respectively. For 
those patients who were on ICS, the mean daily beclomethasone equivalent 
dose was 1371.4 土 546.0 meg. Group 1 COPD patients had a similar 6 minute 
walk distance as the Group 2 COPD patients (p=0.06). However, the Borg 
score was much higher in the Group 2 than the Group 1 COPD patients 
(p<0.001). None of our subjects were on long term oxygen therapy. The mean 
(SD) of the duration of smoking cessation was 8.6(10.3) years. 
The median [IQR] 8-isoprotane level in the EBC of COPD patients and 
, controls were 14.2 [9.5-26.4] and 6.0 [4.2 - 9.7] pg/ml respectively, with a 
higher level in the COPD patients than controls (p<0.001). The data are shown 
in Figure 1. Patients with more severe COPD (Group 2 COPD) had a higher 
level of 8-isoprostane (19.3 [12.0-39.5] pg/ml) in the EBC than those with 
mild to moderate COPD (group 1 COPD) (12.5 [7.1-19.2] pg/ml) (p=0.045). 
8-isoprostane level did not differ between the COPD patients who were on 




Table 1. Demographics of the COPD and control subjects 
All COPD COPD patients COPD patients Control 
patients with FEVi>50% with FEVi<50% subjects 
predicted Predicted 
(n=32) (Group 1 COPD) (Group2 COPD) (n=18) 
(n= 14) (n=18)  
~Age (years) 72 士 9 72 士 6 72 士 11 73 士 5 
Sex (M/F) 28/4 IVl \3/5  
FEVi (L) 0.97 士 0.49* 1.39 士 0.45# 0.65 士 0.17 1.95 士 0.43 
FEV1% 51.5 ±22.4* 72.2 士 16.1# 35.3 士 9.5 121.6 士 21.3 
predicted  
FVC (L) 1.73 士 0.65* 2.13±0.66# 1.42 士 0.45 2.22 士 0.50 
FVC % 64.5 ± 19.3* 78.3 ± 17.5# 53.8 士 12.9 97.2 士 1 7 . 6 ^ 
predicted — 
FEV1/FVC 55.9 士 15.0* 65.7 士 11.0# 48.3 壬 13.4 87.8 士 4.1 
Smoking h a b i t s 4 1 . 5 ±24.3* 34.8 士 19.2 45.6 ±27.0 0 
(pack-year)  
BMI(kg/m') 22.8 士 4.6* 23.7 士 4.1 22.0 ±4.9 25.6 土 2.2 
Blood 4.98 ±2.36 4.14 ± 1.37 5.63 士 2.77 4.03 士 1 . 2 4 ~ 
neutrophil count 
(xlO^/L)  
Blood 0.28 ± 0.22 0.27 ±0.18 0.29 ± 0.25 0.17 士 0.15 
eosinophil count 
(xlO^/L)  
Blood monocyte 0.54 士 0.21 0.53 士 0.23 0.55 士 0.19 0.46 土 0.18 
count (xlO^/L)  
6 min walk test 288.3 土 113.5 314.1 ±132.8 268.2 士 95.0 -
Jm)  
Borg score 4.0 士 3.4* 1.4 士 2.4# 6.1 土 2.5 0 
ICS use (n) 21* 8 13 0 
Theophylline H* 4 7 0 
use (n)  
Data were presented as mean 士 SD 
* p value <0.05 between COPD and control groups 




Figure 1. The level of 8-isoprostane in the exhaled breath condensate of 
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ICS and 12.6 [7.4-19.1] pg/ml in the steroid naive group, p=0.09). 8-
isoprostane level in EBC did not correlate with FEVi/FVC ratio (r=-0.27, 
p=0.14), FEVl percentage predicted values (r=-0.31, p=0.08), 6 minute walk 
distance (r=0.07, p=0.72) and degree of dyspnoea as measured by Borg score 
(r=0.29，p=0.12) in COPD patients. However, if control subjects and COPD 
subjects were all included in the analysis, 8-isoprostane value showed a 
negative correlation with the FEVi % predicted value (r=-0.51, p <0.001). 
The median [IQR] GROa level was lower in the EBC of COPD subjects than 
controls (45.4 [44.5-46.2] pg/ml versus 46.0 [45.6-47.3] pg/ml respectively, 
p=0.02). The data are illustrated in Figure 2. There was no significant 
difference in the EBC GROa levels between Group 1 and Group 2 COPD 
patients (45.3 [44.5-46.5] pg/ml versus 45.4 [44.5-46.0] pg/ml respectively, 
p=0.92). COPD patients who were on ICS therapy did not differ in their EBC 
GROa level from that of the steroid naive patients (45.8 [44.5-46.4] pg/ml in 
ICS group versus 45.3 [44.5-45.5] pg/ml in steroid naive group, p=0.20). The 
EBC GROa level in COPD patients did not correlate with the FEVi/FVC ratio 
(r=-0.02, p=0.91), FEVl percentage predicted value (r=-0.146, p=0.43), Borg 
score (r=-0.09, p=0.66) or 6 minute walk distance (r=-0.35, p=0.06). 
The median [IQR] MCP-1 level in EBC did not differ in patients with COPD 
from controls (5.7 [5.3-6.4] pg/ml versus 5.7 [5.5-6.4] pg/ml respectively, 
p=0.94). Patients on ICS therapy did not differ in their EBC MCP-1 levels 
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[5.3-6.4] pg/ml respectively, p二0.50). In COPD patients, MCP-1 level in the 
EBC did not correlate with FEVi percentage predicted value (r=-0.18, 
p=0.32), Borg score (r=0.07, p=0.72) or 6 minute walk distance (r=-0.12, 
p=0.51). 
There was no correlation between the EBC levels of 8-isoprostane, GROa and 
MCP-1. The EBC levels of 8-isoprostane, GROa and MCP-1 did not correlate 
with the differential white cell count in the peripheral blood of COPD patients 
except that 8-isoprostane correlated with the absolute monocyte count in 
peripheral blood (r=0.50, p<0.01). 
Ten healthy adults (5 males and 5 females) aged 23 to 38 years had EBC 
collected and measured for repeatability testing of the biomarkers. The 
differences between the majority of the paired measurements were within 士 2 
standard deviations (mean differences -0.03 士 0.32，1.31 土 2.16’ -0.46 士 1.16 
pg/ml for 8-isoprostane, GROa and MCP-1 respectively). The coefficients of 
variation for 8-isoprostane, GROa and MCP-1 were 6.7%, 2.6% and 10.6% 




Figure 3 Bland and Altman's Plot of the repeatability of 8-isoprostane, GROa 
and MCP-1 in the exhaled breath condensate of normal controls 
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3.2 Patients with asthma and corresponding control subjects 
Fifty-four asthma subjects and 20 age and sex-matched controls were recruited 
for this study. Subjects with asthma had a lower pre-bronchodilator FEVi and 
FEVi % predicted value than the control group. In addition, the asthma 
subjects had a higher incidence of atopy by skin prick test, a higher serum IgE 
level and peripheral blood eosinophil count than the control subjects. Subjects 
who were on ICS did not differ from those not on ICS in terms of their lung 
function and atopic status. The clinical and physiological details of the 
subjects are summarized in Table 2. None of the subjects who were steroid 
naive were on inhaled or oral long acting beta agonist (LABA) or oral 
theophylline. Among the subjects on ICS, 8 were on inhaled LABA and 1 on 
oral theophylline respectively. 
The median [IQR] eotaxin level was significantly higher in the asthmatic 
subjects than the controls (18.1[17.3-19.4] vs 17.4[16.3-18.0] pg/ml, p二0.01). 
Subjects on ICS had a higher level of eotaxin than the steroid naive 
(18.5[17.7-20.1] vs 17.9[17.0-18.6] pg/ml, p=0.02) and the control groups 
(18.5[17.7-20.1] vs 17.4[16.3-18.0] pg/ml, p = 0.001.). The eotaxin levels in 
EBC in the asthma and control subjects are shown in Figure 4. 
The level of MDC in the EBC of the subjects is illustrated in Figure 5. There 
was no statistically significant difference in the MDC level between the 




Table2. Clinical and physiological details of the subjects. 
Controls All asthma Asthma Asthma 
subjects subjects not subjects on 
on ICS ICS 
(n=20) (n 二 54) (n=25) (n=29) 
Age(yrs) 39.8(10.6) 40.2(11.9) 39.4(13.4) 40.8(10.6) 
Sex (M/F) 9/11 20/34 8/17 12/17 
BMI (kg/m^) 23.8(4.9) 23.4(4.5) 22.4(4.3) 23.8(4.9) 
pre bronchodilator 2.87(0.70) 2.22(0.76)* 2.33(0.77) 2.13(0.75) 
FEVi(L) 
pre bronchodilator 3.07(1.07) 2.82(0.88) 2.90(0.92) 2 75(0 85) 
FVC(L) 
FEVi % predicted 103.1(15.1) 81.7(20.8)* 85.0(23.0) 78.7(18.7) 
FVC % predicted 94.6(26.8) 88.2(17.3) 89.8(20.9) 86.9(13.8) 
FEVi/FVC 85.4(20.6) 78.7(12.5) 80.7(12.2) 77.0(12.6) 
Atopy (+ve) (n[%]) 10[50] 48[89] 21 [84] 27[93] 
IgE (kiu/L) 69.4(79.0) 305(354.8)* 265.6(281.2) 340(409.5) 
Eosinophil count 0.14(0.09) 0.27(0.19) • 0.23(0.19) 0 31(0 19) 
(XI0^) 
ACQ score ^ 1.4(0.9) 1.3(0.9) 1.4(0.9) 
Values are expressed as mean and SD unless otherwise stated 
BMI = body mass index 
ICS = inhaled corticosteroid 
NA = not applicable 
ACQ = asthma control score by Juniper et al [Juniper et al., 1999] 




Figure 4. Level of eotaxin in exhaled breath condensate of asthma and control 
subjects. 
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median (IQR) concentration of MDC in EBC than the steroid naive 
(120.4[117.8-124.6] vs 117.4[116.1-119.3] pg/ml, p =0.01) and the control 
groups (120.4[117.8-124.6] vs 117.2[116.3-119.6] pg/ml, p =0.02). 
The levels of eotaxin and MDC in the asthma group on different dosages of 
ICS are shown in Table 3. The dose of ICS was classified according to the 
GINA guideline [National Heart LaBI, World Heath Organisation, 2004]. 
Four, 10 and 15 subjects were on low dose (<500mcg beclomethasone 
diproprionate [BPD] equivalent dose/day), median dose (500 to lOOOmcg 
BPD/day) and high dose ICS (>1000mcg BPD/day), respectively. The mean 
(SD) dose of ICS for the group on the low to medium dosage of ICS was 
614.29 (250.71) and that on high dosage of ICS was 1927(531) meg/day BPD 
equivalent. No difference in the concentration of eotaxin and MDC was 
observed in subjects on low to medium versus those on high dose ICS. 
Twenty-one, 32 and 37 subjects had onset of asthma before age of 10, 20 and 
30 years respectively. Comparison of the EBC eotaxin and MDC 
concentrations in subjects with different age of onset of asthma (<10 years vs 
>10 years; <20 years vs >20 yrs; <30 years vs >30 years) showed no 
statistically significant differences in their levels if we used 10’ 20 and 30 as 
the cut off values for age. There was also no difference between the EBC level 
of eotaxin and MDC between the atopic and non-atopic asthma subjects. 
There were no correlations between the EBC level of eotaxin and MDC when 
compared to lung function (FEVi, FEVi percentage predicted, FEVi/FVC 
( » 
32 
Table 3. Levels of eotaxin and MDC in exhaled breath condensate of asthma 
subjects on different dose of inhaled corticosteroids. 
Dose of ICS/day Eotaxin MDC 
< lOOOmcg (n= 14) 18.57(17.73-19.86) 120.37(119.96-123.94) 
>1000mcg (n=15) 19.28(17.45-20.29) 118.72(116.25-126.41) 
ICS = inhaled corticosteroid (beclomethasone diproprionate equivalent dose) 
Levels eotaxin and MDC were presented as median (IQR) 
I » 
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ratio), serum IgE level, and blood eosinophil count in all the asthmatic 
subjects as a group. In addition, the levels of these markers did not correlate 
with the disease severity ACQ score devised by Juniper et al. [Juniper et al, 
1999]. In the steroid naive asthmatics, MDC level correlated positively with 
serum total IgE level (r = 0.41，p = 0.04) (Figure 6). The EBC eotaxin level 
did not show correlation with the EBC MDC level. 
Concerning the reproducibility for the measurement of eotaxin and MDC in 
the EBC, six healthy adults aged 22-38 years had their EBC collected for six 
consecutive days. The mean (range) CV for measuring their exhaled eotaxin 




Figure 6. Relationship between exhaled breath condensate level of MDC and 
total serum IgE level. 
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4.1 Exhaled 8-isoprostane, GRO-a and MCP-1 of patients with 
COPD and corresponding control subjects 
The results of this study showed that exhaled 8-isoprostane was increased in 
patients with COPD when compared to the control group. The concentration 
of exhaled 8-isoprostane was increased in the more severe COPD patients 
(FEVI <50% predicted) than the less severe ones (FEVI>50% predicted). In 
contrast to 8-isoprostane, the concentration of exhaled GRO-a was higher in 
the control group than the COPD subjects. However, there was no significant 
difference in MCP-1 levels in the EBC between patients with COPD and the 
control group. In the COPD subjects, the levels of 8-isoprostane and GRO-a in 
the EBC were not different from those of the subjects who were taking or not 
taking ICS therapy. This may suggest that ICS may not be effective in 
suppressing these two inflammatory markers in the COPD airway. 
The production of 8-isoprostane in vivo occurs either via an enzymatic 
independent pathway or a cyclo-oxygenase dependent pathway involving 
cyclo-oxygenase 1 and/or cyclo-oxygenase 2 [Pratico et al., 1995; Klein et al., 
1997; Montuschi and Curro, 1999]. In the non-enzymatic pathway, 8-
isoprostane is formed by free radical peroxidation of arachidonic acid, which 
is generated from membrane phospholipid by phospholipase A2 [Wang et al, 
1995]. Because 8-isoprostane is chemically stable, specific for in vivo lipid 




peroxidation and oxidative stress [Montuschi and Kharitonov et al., 2000], 
The measurement of 8-isoprostane as a marker of oxidative stress in various 
pulmonary diseases has yielded promising results. 8-isoprostane level was 
increased in the urine sample and in plasma of patients with COPD, smokers, 
and patients with cystic fibrosis [Pratico et al., 1998; Brown and Kelly, 1994], 
suggesting that systemic oxidation was present in these individuals. Local 
oxidative stress in the respiratory tract was confirmed by previous studies 
which revealed that 8-isoprostane was raised in the BAL fluid of patients with 
interstitial lung disease [Montuschi et al., 1998], in breath condensate of 
patients with asthma [Montuschi and Corradi et al. 1999], COPD [Montuschi 
and Collins et al., 2000], cystic fibrosis [Montuschi and Kharitonov, 2000], 
acute respiratory distress syndrome [Carpenter et al., 1998] and obstructive 
sleep apnoea [Carpagnano et al., 2002]. Our study showed a higher 
concentration of 8-isoprostane in the breath condensate of COPD patients with 
FEVK 50% than those with FEV1>50%, suggesting that higher oxidative 
stress was present in the airway of patients with more severe COPD. 
In this current study, a positive correlation was observed between peripheral 
blood monocytes count and the level of 8-isoprostane in the EBC. Monocytes 
are precursors of macrophages [Fan et al., 2000]. The number of macrophages 
in tissue and alveolar space increased 25-fold in patients with emphysema as 
- compared to normal smokers [Retamales et al, 2001]. Macrophages 
accumulated in site of alveolar wall destruction in patients with emphysema 




both BAL fluid and induced sputum was observed in patients with COPD 
[Aaron et al., 2001; Culpitt et al., 1999]. The number of lung macrophages 
correlated not only with the degree of emphysema and the degree of small 
airway disease in COPD, but also with the severity of COPD [Jeffery et al., 
1998; Finkelstein et al., 1995; Di Stefano et al., 1998]. The accumulation of 
macrophages in the airway of patients with COPD is the consequence of 
enhanced recruitment of monocytes from the circulation in response to 
cigarette smoking [Barnes et al., 2003; Tetley, 2002; Traves et al., 2004]. 
Alveolar macrophages secrete elastases such as matrix metalloproteinases 
(MMPs) [Punturieri et al., 2000; Russell and Thorley et al.’ 2002], which 
contribute to damage of extracellular matrix (ECM) of the lungs and tissue 
injury, either by directly degrading components of ECM including collagen, 
elastin, and connective tissue proteins, or indirectly inactivating alpha 1-
antitrypsin, an inhibitor of serine proteinase, leading to increased serine 
protease activity [Tetley, 2002]. In vitro study revealed increased mRNA 
expression of MMPl and MMP9 in the macrophages from BAL fluid of 
subjects with emphysema [Finlay et al., 1997]. The expression of MMP2 and 
MMPl4 in the macrophages increases in emphysematous tissue [Ohnishi et 
al., 1998]. Macrophages from patients with COPD demonstrated enhanced 
elastolytic activity [Russell and Culpitt et al., 2002; Lim et al., 2000], and 
expression of MMPl and MMP2 proteins [Segura-Valdez et al., 2000]. The 
‘ role of MMPs in emphysema development was illustrated by a study with 
guinea pigs, which upon exposure to cigarette smoke up to 8 weeks, developed 




collagenase mRNA in the macrophages [Selman et al., 1996]. Taken together, 
these studies suggest that macrophages contribute to the development of 
emphysema by secreting a variety of elastases and this may be triggered by 
oxidative stress brought about by stimulus like cigarette smoke. 
One earlier study aiming at investigating the impact of smoking cessation on 
the proliferative activity in bronchial epithelium (a biomarker for lung cancer 
risk) has shown that although the proliferative activity in bronchial epithelium 
decreased gradually in a time dependent fashion, the level of proliferation 
could be detectable in the ex-smokers who had given up smoking for more 
than 5 years. The data suggested that in ex-smokers, proliferative activity 
triggered by cigarette smoke was present as a result of smoking induced tissue 
damage [Lee et al., 2001]. Serum carcinoembryonic antigen (CEA) was found 
to be associated with neutrophils and white blood cell in smokers without 
malignant diseases [Kashiwabara et al, 2001]. Peripheral blood CEA and 
neutrophil concentration in ex-smokers without malignant diseases showed a 
decreasing trend over 3 years of smoking cessation, as compared to current 
smokers, but the level was still higher than healthy non-smokers. Moreover, 
this study revealed a weak correlation between the decline of CEA and the 
neutrophil concentration after smoking cessation in ex-smokers. The authors 
suggested that a high concentration of CEA in ex-smokers regulated 
neutrophil concentration, and the influence of past smoking was present in ex-
smokers [Kashiwabara et al., 2001]. Cytochrome P450 lAl and IBl are 




2004]. The expression of both enzymes in normal lung tissue of ex-smokers 
(with mean packyear of 61 years and mean duration of smoking cessation 12 
years) and in smokers was augmented as compared to non smokers. However, 
the expression of both enzymes was not significantly different in smokers and 
ex-smokers, indicating that long term smoking and deposits of tobacco smoke 
resulted in a sustained increase of both enzymes in ex-smokers [Kim et al, 
2004]. Taken together, these studies reveal that cigarette smoking imposes a 
long term impact on the respiratory system of ex-smokers. Elastolytic enzyme 
activity may be important in the development of pulmonary emphysema as 
extracellular elastolytic acitivtiy remained elevated in the BAL fluid of ex-
smokers [Smith et al., 1988]. In a rat model of emphysema, expression of 
markers of oxidative stress and apoptosis were enhanced in lung alveolar cells. 
In contrast, when the model was treated with a combination of agents against 
the development of emphysema and inhibition of apoptosis, the markers of 
oxidative stress declined. The authors of this study suggested that apoptosis of 
lung alveolar cells contributed to increased expression of oxidative stress, and 
a positive feedback loop between apoptosis of lung alveolar cells and 
oxidative stress was crucial in human and experimental emphysema [Zlotnik 
. et al., 1999]. In the present study, the patients with COPD were heavy smokers 
in the past and stopped smoking for a significant period (mean time 8 years). 
The level of oxidative stress, as reflected by exhaled 8-isoprostane, was 
“ elevated when compared to control subjects. The high level of oxidative stress 
in these patients might further contribute to ongoing cell death and 
inflammation. These patients in contrast had less GRO-a in exhaled breath 
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than control subjects. Apart from regulation of the trafficking of neutrophils, 
GRO-a has been shown to participate in the normal wound healing process 
[Rennekampff et al., 1997; Devalaraja et al., 2000]. It has been suggested that 
GRO-a may take part in growth and repair of the lungs [Witherden et al., 
2004]. It may therefore be reasonable to speculate that augmented level of 
oxidative stress but a reduced level of GRO- a might be a consequence of 
excessive cell death and a dampened wound healing in these patients. 
The current study has demonstrated no differences in the EBC MCP-1 
concentration between COPD patients and the control subjects. It remains 
controversial whether the level of MCP-1 in the lungs of healthy smokers or 
patients with COPD is increased or not. de Boer et al have shown a difference 
in the epithelial MCP-1 rtiRNA concentration in bronchiolar and alveolar 
tissues between patients with COPD and their controls. They were however 
unable to show such a difference in the protein level [de Boer et al, 2000]. 
Traves et al reported that the level of MCP-1 in BAL fluid in patients with 
COPD did not differ from that in non smokers [Traves et al., 2002]. 
Pulmonary elastin breakdown can lead to pulmonary emphysema as shown by 
an animal study that endobronchial administration of elastase caused 
pulmonary elatsin breakdown, which could be measured by urinary excretion 
of elastin peptides [JanofF et al, 1983]. Augmented level of neutrophil elastase 
“ activity was found in the plasma of cigarette smokers and patients with alpha-
1 antitrypsin deficiency [Weitz et al., 1987; Weitz et al., 1986], A high 




MCP-1 from alveolar cells [Witherden et al, 2004]. In addition, proteolytic 
enzymes, such as MMPsl, 3，and 9, were capable of cleaving extracellular 
chemokines [McQuibban et al., 2001]. Based on these observations, we 
speculate that the airway of COPD patients may have been damaged by an 
increased level of neutrophil elastase and other proteases, resulting in cleavage 
of the extracellular chemokines such as MCP-1. The increased proteolysis and 
inflammation in these ex-smoking COPD subjects thus lead to progressive 
damage of the airway tissue. 
DNA is tightly bound by hi stone proteins to form nucleosomes to prevent gene 
transcription [Beato, 1996]. Acetylation of histone residues results in 
unwinding of the DNA, and binding of transcription factors and RNA 
polymerase II，thus enhancing gene transcription [Beato, 1996; Allfrey et al., 
1964; Wu et al.’ 1986]. The process of acetylation is regulated by histone 
acetyltransferase (HAT) and histone deacetylase (HDAC) such as HDAC2 
[Sternglanz, 1996]. HAT enhances hyperacetylation of histories and gene 
expression [Grunstein, 1997; Sambucetti et al., 1999], whereas HDAC causes 
deacetylation of histories, resulting in rewinding of DNA and inhibition of 
gene transcription [Janknecht and Hunter, 1996]. Increased gene transcription 
is a consequence of enhanced histone acetylation activity [Imhofet and 
Woffle, 1998]. Corticosteroid exerts its anti-inflammatory effect by recruiting 
HDAC2 protein to suppress pro-inflammatory gene transcription. The 
beneficial effect of corticosteroids for patients with COPD remains to be 




inflammatory actions of corticosteroids [Barnes et al.’ 2004], Neither inhaled 
corticosteroid nor systemic steroid inhibited the activation of inflammatory 
cells and release of inflammatory cytokines in patients with severe or stable 
COPD [Keatings et al., 1997; Culpitt et al., 1999]. Long term ICS therapy did 
not alleviate inflammation in COPD [Hattotuwa et al., 2002]. Oxidative stress 
reduced activity of HDAC and promoted expression of inflammatory 
cytokines [Tomita et al., 2003; Rahman, 2003]. Based on these observations, 
Barnes et al have proposed a novel molecular mechanism that accounts for 
smoking induced glucocorticoid resistance in COPD through impairing the 
function of HDAC2 [Barnes et al., 2004]. Our study has found no difference in 
the markers (8-isoprostane, GRO-a and MCP-1) between ex-smoking COPD 
patients who were on ICS or not on ICS. A recent study of a group of very 
severe COPD patients (stage 4 according to GOLD guideline), who were ex-
smokers and receiving either oral or inhaled steroid, has revealed decreased 
HDAC2 activity, increased expression of IL-8 mRNA, and augmented 
acetylation of IL-8 promoter but there was no difference in the HAT activity 
as compared with non-smokers in peripheral lung tissue [Ito et al., 2005]. 
Whether ex-smoking COPD subjects have glucocorticoid resistance similar to 
smoking COPD subjects deserves more study. 
4.2 Exhaled eotaxin and MDC from patients with asthma and 
corresponding control subjects 
Lung eosinophilia, resulting from a network of cytokines and chemokines, is a 




[Humbles et al., 1997], IL-5 was shown to regulate the release of eosinophils 
from bone marrow to the lung tissue and thus induced lung eosinophilia. This 
animal study by Humbles et al [Humbles et al., 1997] showed that lung 
eosinophilia was associated with eotaxin in the early phases of eosinophil 
recruitment after OVA challenge. This finding was also supported by a study 
conducted by Lamkhioued and colleagues, in which they observed the 
recruitment of IL-5 primed eosinophils into the airways of asthmatics was 
governed by eotaxin that was constitutively produced by airway epithelial 
cells [Lamkhioued et al., 1997]. This increase in lung eosinophils was not 
paralleled by an increase in eotaxin level in the BAL fluid or bronchial biopsy 
in the late phase allergic reaction [Gauvreau et al., 1999; Brown et al., 1998]. 
This may indicate that eotaxin may play a role in the early allergic reaction, 
but the late phase allergic reaction of eosinophil infiltration in lung is probably 
regulated by other factors than eotaxin such as RANTES, IL-5 and 
granulocyte-macrophage colony stimulating factor (GM-CSF). 
The eotaxin receptor, CCR3, is expressed on the cell surface of eosinophils. In 
addition, the CCR3 receptor can also be found on mast cells, basophils and a 
subset of Th2 cells [Daugherty et al., 1996; Kitaura et al., 1996; Ponath et al., 
1996; Sallusto et al., 1997]. A recent study trying to investigate the role of 
eotaxin in induced sputum in asthma has found that eotaxin correlated with the 
number of eosinophils in induced sputum [Yamada et al., 2000]. On the other 
hand, adhesion of eosinophils to microvascular endothelial cells was enhanced 




(VCAM-1) and intercellular adhesion molecule (ICAM-1) on the endothelium 
[Hohki et al. 1997]. Eotaxin production by the bronchial epithelium was in 
general enhanced by Th2 cytokines [Stellato et al., 1999; Fujisawa et al., 
2000]. An exception to this is IFN-y as it could not stimulate eotaxin 
production in bronchial epithelial cells [Fujisawa et al., 2000]. All the 
evidence suggest that eotaxin plays an important role in eosinophilic related 
inflammation through its ability to regulate the trafficking of eosinophils. 
As eotaxin plays such an important role in airway inflammation in asthma, 
measurement of this marker by EBC collection may offer a novel non-invasive 
monitoring of the disease process in asthma. There has been so far only one 
study in paediatric subjects which found that EBC eotaxin was not different 
between the asthmatic children and controls [Leung et al., 2004]. Our study in 
contrast has found that EBC eotaxin was higher in the adult asthmatics than 
the control subjects. Furthermore, we have found that asthmatic subjects on 
ICS had an even higher eotaxin EBC level than the steroid naive asthmatics. 
This might suggest that the more severe asthmatics requiring ICS had higher 
eotaxin in the airway. The finding of the increased expression of eotaxin in the 
‘ EBC of our adult asthma patients, however, was in agreement with previous 
studies involving blood or sputum collection and sampling of the airway by 
bronchoscopy in adult subjects. In the peripheral blood, Nakamara et al and 
“ Lilly et al [Nakamura et al., 1999; Lilly et al, 1999] demonstrated an increased 
level of eotaxin in patients with asthma when compared to the controls. In 
induced sputum, the eotaxin level was also found to be elevated in asthma 
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patients [Dent et al., 2004; Yamada et al., 2000; Zeibecoglou et al, 2000]. 
Furthermore, in studies involving BAL fluid of asthmatic subjects, the levels 
of eotaxin mRNA and protein were higher in the asthmatics than in the 
controls [Lamkhioued et al., 1997]. Further studies are needed to assess the 
role of EBC eotaxin as a non-invasive marker of airway inflammation in 
asthma. 
There is considerable evidence indicating that MDC and its receptor CCR4 are 
involved in Th2-dominated diseases such as asthma and atopic dermatitis. An 
in vitro study found that MDC was produced by monocytes upon stimulation 
by the Th2 cytokines such as IL-4 and IL-13 [Andrew et al.，1998]. Serum 
and plasma MDC levels were elevated in patients with atopic dermatitis, a 
chronic inflammatory skin disease [Leung et al., 2003; Kakinuma et al., 2002; 
Fujisawa et al., 2002]. In asthma, the expression of MDC by immunostainning 
in airway epithelial cells of atopic asthmatics after allergen challenge was 
elevated when compared to the controls [Panina-Bordignon et al., 2001]. 
MDC was also observed to be up-regulated in BAL samples of atopic 
asthmatics after allergen challenge. In stable asthmatics, MDC level was found 
• to be significantly elevated in BAL obtained from asthmatic adults and EBC 
from children respectively [Lezcano-Meza et al, 2003; Leung et al., 2004]. 
Augmented CCR4-expressing Th2 cells and its ligands MDC in BAL fluid 
“ was also observed in patients with eosinophilic pneumonia [Katoh et al., 
2003]. CCR4 is one of the chemokine receptors found in platelets and 
interestingly, it could be activated by MDC [Abi-Younes et al., 2001]. It was 
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also shown that anti-CCR4 antibody could abolish MDC-induced platelet 
activation [Abi-Younes et al., 2001]. MDC might play a role in allergic 
asthma and atopic dermatitis through its effect on platelet activation in concert 
with production of thromboxane A2 and platelet-activating factor [Page, 1989; 
Page, 1991; Watanabe, 1999; Page and Coyle, 1989; Moritani et al, 1998; 
Takami and Tsukada, 1998]. Our study did not demonstrate any difference in 
the EBC MDC levels between the asthmatic subjects and the controls. Among 
our asthmatic subjects, 88.9% (48 out of 50) had atopy as demonstrated by at 
least one positive reaction to skin test by 8 common aeroallergens. It is well 
known that atopy is mediated by Th2 cell mediated immunity [Ling et al., 
2004; El Biaze et al., 2003; Prescott et al., 1998; Magnan et al., 2000]. We 
thus expected the MDC level to be higher at least in the atopic asthmatics 
when compared to the non-atopic ones or the controls. However, no difference 
in the MDC EBC levels between these groups was observed. Previous studies 
in BAL study found that the level of MDC was raised in asthmatics and the 
controls [Lezcano-Meza et al., 2003] but this was not observed in sputum and 
peripheral blood study [Sekiya et al., 2002], Our result on airway MDC is thus 
in line with the sputum and peripheral study but conflicts with the BAL study. 
Further research in this area is needed for better understanding the role of 
MDC in asthma 
‘ ICS is the first-line therapy for treating asthma. At the cellular level, ICS is 
effective in reducing inflammatory cells involved in the pathogenesis of 
asthma [van der Velden, 1998]. This is illustrated by the fact that tissue 
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eosinophilia in patients with mild-to-moderate persistent asthma could be 
dampened by inhaled beclomethasone therapy in bronchial biopsy studies 
[Hoshino and Nakamura, 1996]. Clinically, treatment with ICS was associated 
with improvement in lung function, symptoms and quality of life of in patients 
with persistent asthma [Barnes, 1998; Barnes, 1993]. This current study has 
revealed that patients with asthma who received ICS therapy had significantly 
higher level of exhaled eotaxin and MDC than their steroid naive counterparts. 
Subjects who were on ICS might have more severe asthma than their steroid 
naive counterpart as ICS was prescribed for this group of asthmatics to 
achieve similar lung function and symptom score as the steroid naive asthma 
subjects. In patients with severe asthma, neutrophils [Wenzel et al., 1999; 
Louis et al., 2000] and neutrophil derived proinflammatory cytokines and 
proteolytic enzymes, for instance, matrix metalloproteinase-9 [Mattos et al., 
2002; Cundall et al., 2003], IL-8 and myeloperoxidase [Jatakanon et al., 
1999], were found to be elevated when compared to patients with mild or 
moderate asthma [Jatakanon et al., 1999; Wenzel et al., 1997], suggesting 
neutrophils activation in severe asthma. Severe asthmatics on ICS have 
predominantly neutrophilic inflammation compared to eosinophilic 
• inflammation. We postulate that the more severe the asthma was, the higher 
the level of exhaled chemokines might be associated with neutrophilic 
inflammation in these patients. 
It was interesting to note that the level of MDC in EBC correlated with serum 
total IgE in the steroid naive asthmatics in the current study. The production 
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of IgE by B cells depends on the presence of IL-4 and IL-13 secreted by 
activated Th2 cells and B cells [Yssel et al., 1998]. IgE stimulated expression 
of MDC receptor CCR4 on murine mast cells [Oliveira and Lukacs, 2001] and 
also enhanced secretion of MDC from murine mast cells. IgE-mediated 
inflammation may possibly play a role in asthma by stimulating production of 
Th-2 specific chemokines such as MDC. 
The lack of association between exhaled eotaxin concentration and 
eosinophils, between exhaled MDC and Th2 cells, and between exhaled MCP-
1 and monocytes in the current study suggests that the trafficking of 
leukocytes to their destination via chemokines is the result of a complex 
system of chemoattractant gradient, adhesion molecules and cell survival 
factors across inflamed tissues and circulation. 
4.3 Technical aspects of EBC assessment 
EBC is a new technique for assessing airway inflammation. It is still at its 
infancy of development and there is so far no standardized method for its 
. collection and measurement. In this study, the machine EcoScreen (Jeager, 
Germany) was used to collect the EBC. The design of EcoScreen consisted of 
a two-way non-rebreathing valve and this design has been shown to be very 
. effective in separating the ambient air drawn in by the subject through 
inhalation from mixing with the exhaled air, and thus avoiding nasal 
contamination and rebreathing contamination. The subjects performing EBC 
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collection were also asked to wear a noseclip during the process. This could 
further prevent contamination of analytes with nasal air, such as leukotrienes, 
which are present in the nose [Montuschi and Barnes, 2002], Considerable 
amount of leukotrienes and prostaglandins are found in saliva [Montuschi and 
Barnes, 2002]. The EcoScreen also contains a salivary trap and quality control 
studies have shown that amylase (a marker of salivary contamination) was not 
detected in the EBC collected by EcoScreen [Mutlu et al., 2001; Montuschi 
and Barnes, 2002]. 
The rate of exhalation varies in different subjects and the total collection time 
in EBC collection also varied from 5 to 10 minutes in previous studies [Mutlu 
et al., 2001]. Both the rate of exhalation and the duration of collection can 
potentially affect the volume of EBC collected and the concentration of 
analytes generated in each subject. There were a lot of controversies regarding 
how to deal with these methodological issues. This has generated a lot of 
discussions over the "correct" or "standard" way to collect EBC. However, no 
consensus has been reached so far. Not only are the rate of breathing and the 
duration of breathing important during EBC collection, other factors like the 
temperature of the device used for condensation can also potentially affect the 
concentration of some unstable solutes, such as leukotrienes, which is known 
to be unstable at -5 to +5 °C [Mutlu et al., 2001]. The American Thoracic 
Society has tried to draft consensus guideline and recommendation regarding 
the method of EBC collection but agreement has still not been made yet. 
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EBC is believed to contain particles from the airway lining fluid. The exact 
location of the source of these particles remains undefined (like the 
contribution from the alveoli) [Mutlu et al., 2001]. The increase in EBC levels 
of analytes in earlier studies in different pulmonary disorders, as suggested by 
Effros et al., might be a consequence of either an increase in mediator 
concentration in the airway lining fluid or an increase in droplet formation in 
those subjects with airway diseases [Effros et al., 2002]. When measuring the 
concentration of a particular solute in the EBC, some authorities have 
suggested the use a dilution factor to adjust the concentration between 
samples. This dilution factor is to adjust the dilution of the respiratory droplets 
by water vaporization. The choice of this dilution factor is preferably a non-
inflammatory and stable mediator, like electrolyte concentration, conductivity 
or urea concentration [Effros et al., 2002]. Whether dilution factor is the 
solution for adjustment of inter-subject or intra-subject variations in the 
concentration of EBC solute requires further study to answer. 
In an attempt to assess any intrasubject variations of the chemokines or 8-
isoprostane we measured, repeatability test was performed. During the 
repeatability tests, we asked each subject to have EBC collected on at least 2 
consecutive days. The concentration of the biological markers in the EBC was 
then measured in one batch. We used standardized methods, the Bland and 
Almand method [Bland and Altman, 1986] or the co-efficient of variation 
calculation, to assess repeatability. In this present study, we have assessed the 
8-isoprostane, MCP-1 and GRO-a using Bland and Altman method, and 
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eotaxin and MDC using co-efficient of variation calculation. The Bland and 
Altman method utilizes a plot, in which differences of individual subjects 
between the tests are plotted against individual means. Random variation is 
said to occur if the y-axis of the plot shows a general tendency for the second 
measurement to be either higher or lower than the first measurement of the 
same subject [Atkinson and Nevill, 1998]. Normal variation in a particular test 
is considered when the results of the test lie between the 95% of the limits of 
agreement (LOA), which equals to 士2 standard deviations of the differences 
between test 1 and test 2 of the subjects [Atkinson and Nevill, 1998]. In the 
Bland and Altman plots in this study, the majority of the differences in the 
concentration of exhaled 8-isoprostane, MCP-1 and GRO-a between day 1 and 
day 2 lied within the 95% LOA and thus reflected good repeatability of the 
exhaled biomarkers collected from each subject on two separate days. For the 
co-efficient of variations, a value of less than 10% is in general considered to 
have good agreement between two tests. Our repeatability results of eotaxin 
and MDC has shown a CV value of 5.2% and 5.5% respectively, and thus 
indicated a good agreement between the tests done on the 6 consecutive days 
in our subjects. 
The use of EBC in assessing lower airway inflammation is still in 
experimental stage. No consensus has been reached on the standardization for 
‘ the collection and analysis of EBC. The lack of high sensitivity 
immunochemical or colorimetric assasys is another methodological pitfall of 




concentration of the markers in EBC, it is therefore necessary to adjust this 
dilution factor between samples. Unforturnately, there is at present no standard 
way to solve this problem. 
The current study was a cross-sectional study aiming at comparing the exhaled 
levels of various biomarkers in subjects with asthma and COPD against the 
controls. Although we have found that subjects with asthma and COPD on 
ICS did not have reduction in biomarkers in the EBC when compared to the 
controls, we could not conclude whether ICS was effective in reducing the 
level of these biomarkers. A longitudinal study instead of a cross sectional 




The epithelial lining fluid contains an array of proteins originated from 
different cellular sources, including (1) lung specific proteins (such as 
surfactant proteins A to D); (2) serum like antigens, for instance albumin; (3) 
proteins secreted by inflammatory cells, for example eotaxin; and (4) proteins 
with various functions (such as cathepsin D which is involved in remodeling 
process during fibrogenesis) [Noel-Georis et al., 2001], It has been proposed 
that EBC may reflect the composition of ELF and thus the above proteins may 
be captured in EBC. Proteomic analysis has revealed that proteins weighing 14 
to 66 kDa with isoelectric point ranging from 5 to 8 were detectable in EBC 
[Griese et al., 2002], although the identity of the proteins were unknown. 
When coupled with mass spectrometry, proteomic analysis of EBC has 
demonstrated that the content of keratin in EBC from healthy smokers was 
much higher than that of non-smokers [Gianazza et al., 2004]. Therefore, 
proteomic analysis of the content of EBC may possibly provide a useful 
research tool for confirmation of disease markers in lung disorders, 
identification of proteins of unknown functions, and studying the effect of 
drug intervention on the structure of proteins and composition of ELF. 
- Apart from detecting disease markers of inflammatory lung diseases, EBC has 
been utilized to investigate marker and gene mutation of lung cancer. 




small cell lung cancer (NSCLC), was elevated in the EBC of patients with 
NSCLC and its level in EBC decreased after treatment [Carpagnano et al., 
2004]. On the other hand, a group of German researchers not only detected p-
actin gene, the house-keeping gene, in the EBC from both healthy volunteers 
and patients with NSCLC, but also gene mutations in the EBC samples from 
the patients. The latter study has shed some light in investigating genetics of 
various lung disorders, for instance, the epigenetics of lung cancer. 
The analysis of breath constituent is a simple technique. It provides another 
tool to investigate markers of various diseases non-invasively without 
resorting to invasive techniques like bronchial biopsy. It is an area of great 
research interest. In airway diseases like asthma and COPD, the non-invasive 
nature of EBC allows repeated measurements to be done and this may help 
assessing the severity and guiding the management of these diseases. 
Measurement of biomarkers in airway diseases can potentially lead to better 
understanding of the airway inflammation and disease progress in affected 
patients. Our study has added more information to the growing literature on 






This is the first study to confirm that it is feasible to detect chemokines (MCP-
1，GRO-a, eotaxin and MDC) in the EBC in adults. In addition, we have 
shown that these markers could be measured with good repeatability in normal 
subjects. 
In our group of ex-smoking COPD patients, we have found that 8-isoprostane 
EBC level was higher in patients with more severe COPD (FEVi <50% 
predicted) than mild-to-moderate cases. The result suggests that there is more 
oxidative stress in patients with more severe COPD and poorer lung function. 
The neutrophilic and monocytic chemokines (GRO-a and MCP-1) could be 
measured in the EBC and there was a tendency for GROa to be suppressed in 
COPD patients. GRO-a has a growth promoting and repair effect and its 
suppression may contribute to the airway inflammation and destruction in 
COPD patients. ICS has no effect on the airway inflammatory markers 
measured in this study. 
In the asthmatic subjects, we have shown that the EBC eotaxin level was 
higher in asthmatics than the controls. As eotaxin is a potent eosinophil 
chemoattractant, the finding supports that eosinophilic inflammation plays a 
crucial role in asthma. EBC eotaxin and MDC levels were higher in asthmatics 




that the subjects on ICS treatment had more severe underlying airway 
inflammation. 
Further studies are needed to assess the role of chemokines in the pathogenesis 
of COPD and asthma. More research is needed to investigate the use of EBC 
8-isoprostane, MCP-1, GRO-a, eotaxin and MDC as non-invasive biomarkers 
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